Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan

• Published in: Journal of gastroenterology and hepatology Vol. 29; no. 5; pp. 1119 - 1125
• Main Authors: Chang, Yu-Ting, Chang, Ming-Chu, Huang, Kai-Wen, Tung, Chien-Chih, Hsu, Chiun, Wong, Jau-Min
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.05.2014
• Subjects: Adult; Aged; Aged, 80 and over; biliary tract carcinomas; Biliary Tract Neoplasms - genetics; Biliary Tract Neoplasms - pathology; Biliary Tract Neoplasms - therapy; BRAF; Cell Transformation, Neoplastic - genetics; Codon - genetics; EGFR; Exons - genetics; Female; Humans; KRAS; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins p21(ras); ras Proteins - genetics; Receptor, Epidermal Growth Factor - genetics; survival; Taiwan; biliary tract carcinomas; BRAF; KRAS; EGFR; survival

Background and Aim Biliary tract carcinomas (BTCs) are difficult to diagnose and treat. Epidermal growth factor receptor (EGFR) represents a therapeutic target for the BTCs. Mutations of the EGFR gene and the activation of its downstream pathways, including KRAS and BRAF, predict the sensitivity to...